IDEXX Laboratories, Inc. vs Global X Defense Tech ETF — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Global X Defense Tech ETF trades at $70.12. The key difference: Global X Defense Tech ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | SHLD | |
|---|---|---|
Market Cap | $46.22B | — |
Sector | Health | Sector/Thematic |
52-Week High | $766.68 | $78.02 |
52-Week Low | $526.44 | $58.20 |
Enterprise Value | $47.12B | — |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
SHLD, the Global X Defense Tech ETF, trades at $70.08, up 0.33% with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights institutional accumulation, including Focus Financial Network increasing its stake by 55.4% in Q2 2026 (Defense World, 2026-08-11). The ETF provides diversified exposure to global defense stocks amid rising military spending trends.
Outlook is supported by geopolitical tensions and defense budget growth, but risks include policy shifts and valuation concerns. Analysts note SHLD's lower fees and tech focus versus peers, with a dividend of $0.19 scheduled for July 2026. Key resistance is at $70, with support at $69.
Trailing returns across standard periods
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →